Remedium Lifecare Limited has announced its consolidated financial results for the quarter and half-year ended 30 September 2025, reporting strong operational momentum and continued progress in business expansion.

For Q2 FY26, consolidated revenue from operations stood at Rs 1.11 billion, while total income reached Rs 1.14 billion. The company reported consolidated profit before tax of Rs 104.37 million and profit after tax of Rs 38.62 million. Earnings per share were Rs 0.10, doubling from Q1 FY26.

For the half-year period, consolidated revenue from operations totalled Rs 2.24 billion, with total income at Rs 2.31 billion. Profit before tax for H1 FY26 was Rs 316.49 million, and profit after tax reached Rs 132.72 million, translating to earnings per share of Rs 0.15. Consolidated total assets stood at Rs 16.23 billion as of 30 September 2025.

Commenting on the results, Mr Adarsh Munjal, Whole-Time Director, said the second-quarter performance reflected the company’s ongoing commitment to operational discipline and strategic expansion. He noted that the consolidated results demonstrate the strength of the company’s portfolio and its ability to scale efficiently. He added that the company expects momentum to continue through the remainder of the financial year as it focuses on profitability, asset strengthening, and sustainable growth.

Remedium Lifecare has recently strengthened its leadership with the appointment of Mr Rambhajan Vishwakarma and Mr Vignesh Laxman Gawde to the Board, signalling enhanced focus on governance, global expansion, and scaling of CDMO capabilities.

The company’s broader strategy—leveraging its global-subsidiary network, including a Singapore entity incorporated in September 2024, and expanding its CDMO service offerings—reinforces its ambition to strengthen and monetise its specialty pharmaceuticals and chemicals business